2021-06-10T00:00:00.000+10:00
Ongoing

CUPID

CUPID
Prostate cancer

A Phase I, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer

A Phase I, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer

Trial overview

Topic

Prostate cancer

Trial registration

Number: NCT04726033

Study details

This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592). TLX592 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours, therefore this study has been designed to assess the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation dosimetry of 64Cu-TLX592.

Further information

For more information regarding this clinical trial click here.

Location

GenesisCare Murdoch – PI: Nat Lenzo

GenesisCare Murdoch – PI: Nat Lenzo :::

GenesisCare Newcastle – PI: Anne Capp

GenesisCare Newcastle – PI: Anne Capp :::

GenesisCare HIG – PI: Anne Capp

GenesisCare HIG – PI: Anne Capp :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.